Slide 1
Slide 1
Slide 1
Slide 1
Slide 1
Slide 1
Slide 2
Slide 2
Slide 2
Slide 2
Slide 3
Slide 3
Slide 3
Slide 3
Slide 3
Slide 3
Slide 3
Slide 3
Slide 3
Slide 3
previous arrow
next arrow

Press

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Press Release | Foster City, Calif. – June 20, 2024- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.

Better detection of tuberculosis in children
with decentralized diagnosis

Press release | Marseille, March 22, 2024– Two articles from one study focusing on decentralising the diagnosis of childhood TB to district hospitals (DH) and primary health centres (PHC) in high tuberculosis incidence countries have just been published in eClinicalMedicine. The study was carried out in six countries with a high incidence of tuberculosis (Cambodia, Cameroon, Côte d’Ivoire, Mozambique, Sierra Leone, and Uganda) as part of the TB-Speed project implemented by the Institut Pasteur (Cambodia), French National Research Institute for Sustainable Development (IRD) (Cameroon), PACCI (Côte d’Ivoire), Instituto Nacional de Saude (Mozambique), Soltis (Sierra Leone), MU-JHU (Uganda), and coordinated by the University of Bordeaux (France)..

 

Our Work

https://www.mujhu.org/wp-content/uploads/2022/03/01-research.png
https://www.mujhu.org/wp-content/uploads/2022/03/Programs.png
https://www.mujhu.org/wp-content/uploads/2022/03/03-Capacity-building.png
https://www.mujhu.org/wp-content/uploads/2023/03/Group-52.png
https://www.mujhu.org/wp-content/uploads/2022/03/05-corporate-social-responsibility.png

Our Partners